Company’s technology enables real-time and personalized control of the therapeutic heat dose in the retina during non-damaging ophthalmic laser treatments.
Our industry-disruptive goal is disease prevention by providing effective and safe early treatments for common diseases that impact the everyday life of millions of people worldwide.
Contact
Jani Tirronen, CEO
Maculaser Oy
Terkko Health Hub, Building 14
Haartmaninkatu 4
00290 Helsinki
www.maculaser.com
Follow Maculaser on social media:
LinkedIn
Twitter
Facebook